Literature DB >> 352258

New in vitro model to study the effect of antibiotic concentration and rate of elimination on antibacterial activity.

S Grasso, G Meinardi, I de Carneri, V Tamassia.   

Abstract

A new apparatus is described which serves to investigate the in vitro antibacterial activity of antibiotics as a function of different concentration time curves. The apparatus can be adjusted to simulate the biexponential serum level curves observed in vivo after oral or intramuscular administration. Preliminary studies were carried out with a cephalosporin derivative, cefazolin, against Escherichia coli and Klebsiella sp. strains simulating initial concentrations of 5, 10, and 20 mug/ml that decreased exponentially with half-lives of 30, 60, and 120 min. Surviving cells were counted at 1-h intervals for 10 h. In all the situations tested there was an initial phase of rapid bactericidal activity followed by a phase of bacteriostatic activity, whose length depended on the drug elimination rate but was relatively independent of the initial concentrations. Bacterial regrowth occurred when the antibiotic concentration fell below the minimum inhibitory concentration of the drug against the strains tested. The antibacterial activity of cefazolin, cephacetrile, and cephradine against E. coli and Klebsiella strains was also investigated, in a medium containing 4% human albumin, simulating the serum level curves observed in humans after an intramuscular dose of 1 g. The results obtained suggest that, for cephalosporins, a longer half-life might be more useful than higher peak levels.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 352258      PMCID: PMC352290          DOI: 10.1128/AAC.13.4.570

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

1.  Pharmacokinetic interpretation of blood levels and urinary excretion data for cefazolin and cephalothin after intravenous and intramuscular administration in humans.

Authors:  E S Rattie; L J Ravin
Journal:  Antimicrob Agents Chemother       Date:  1975-05       Impact factor: 5.191

2.  [Celospor (C 36278-Ba), a new antibiotic of the cephalosporin series: pharmacokinetics and clinical trial].

Authors:  P N Maurice; W Riess; A Welke; K Amson
Journal:  Schweiz Med Wochenschr       Date:  1973-05-12

3.  Antibacterial action of "broad-spectrum" penicillins, cephalosporins and other antibiotics against Gram-negative bacilli isolated from bacteremic patients.

Authors:  N H Steigbigel; C E McCall; C W Reed; M Finland
Journal:  Ann N Y Acad Sci       Date:  1967-09-27       Impact factor: 5.691

4.  Trimodal response of Escherichia coli and Proteus mirabilis to penicillins.

Authors:  D Greenwood; F O'Grady
Journal:  Nature       Date:  1970-10-31       Impact factor: 49.962

5.  A simple dilution analog computer for simulation of drug distribution processes.

Authors:  E L Rowe; W Morozowich
Journal:  J Pharm Sci       Date:  1969-11       Impact factor: 3.534

6.  7-(Alpha-(1-methyl-4-pyridinothio)-acetamido) cephalosporanic acid.

Authors:  R E Buck; F Leitner; K E Price
Journal:  Antimicrob Agents Chemother       Date:  1972-01       Impact factor: 5.191

  6 in total
  71 in total

Review 1.  Achieving an optimal outcome in the treatment of infections. The role of clinical pharmacokinetics and pharmacodynamics of antimicrobials.

Authors:  R C Li; M Zhu; J J Schentag
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

Review 2.  Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC.

Authors:  Markus Mueller; Amparo de la Peña; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

3.  Pharmacokinetics and antibacterial activity of daily gentamicin.

Authors:  H Skopnik; R Wallraf; B Nies; K Tröster; G Heimann
Journal:  Arch Dis Child       Date:  1992-01       Impact factor: 3.791

4.  Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacin.

Authors:  Alison K Meagher; Alan Forrest; Axel Dalhoff; Heino Stass; Jerome J Schentag
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

Review 5.  Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases.

Authors:  P S McKinnon; S L Davis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-10       Impact factor: 3.267

6.  Comparative in vitro activity of daptomycin (LY146032) and vancomycin against gram-positive cocci determined using a pharmacokinetic model.

Authors:  J I Blenkharn; J H Darrell
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-08       Impact factor: 3.267

7.  Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats.

Authors:  R Roosendaal; I A Bakker-Woudenberg; M van den Berghe-van Raffe; J C Vink-van den Berg; B M Michel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-10       Impact factor: 3.267

8.  Antipseudomonal activity of simulated infusions of gentamicin alone or with piperacillin assessed by serum bactericidal rate and area under the killing curve.

Authors:  J E Tisdale; M T Pasko; J M Mylotte
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

9.  New in vitro model to study the effect of human simulated antibiotic concentrations on bacterial biofilms.

Authors:  Janus A J Haagensen; Davide Verotta; Liusheng Huang; Alfred Spormann; Katherine Yang
Journal:  Antimicrob Agents Chemother       Date:  2015-04-27       Impact factor: 5.191

10.  Pharmacokinetics and pharmacodynamics of nemonoxacin against Streptococcus pneumoniae in an in vitro infection model.

Authors:  Wang Liang; Yuan-cheng Chen; Yu-ran Cao; Xiao-fang Liu; Jun Huang; Jia-li Hu; Miao Zhao; Qing-lan Guo; Shu-jing Zhang; Xiao-jie Wu; De-mei Zhu; Ying-yuan Zhang; Jing Zhang
Journal:  Antimicrob Agents Chemother       Date:  2013-04-15       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.